Blinatumomab in Ph+ B-ALL: present and perspectives

Oncotarget. 2017 Oct 25;8(55):93309-93310. doi: 10.18632/oncotarget.22071. eCollection 2017 Nov 7.
No abstract available

Keywords: acute lymphoblastic leukemia; blinatumomab; minimal residual disease; philadelphia chromosome; tyrosine kinase inhibitors.

Publication types

  • Editorial